drugset / Trial / NCT01734044

Summary

The project was undertaking by Qilu Hospital of Shandong University and other 13 well-known hospitals in China. In order to report the efficacy and safety of Recombinant Human thrombopoietin combining with Dexamethasone for the treatment of adults with primary immune thrombocytopenia (ITP), compared to High-dose Dexamethasone therapy.

Timeline

Start
2012-07
Primary completion
2014-07
Completion
2014-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexamethasone Small molecule 40 mg Intravenous
Subject recombinant human thrombopoietin Protein / enzyme biologic 300 iu/kg Subcutaneous